Accendatech Luoyang Co., Ltd.

Primary objectives: 1) To evaluate the safety and tolerability of oral administration of ACT001 in NMOSD-ON subjects. 2) To evaluate the pharmacokinetic characteristics of ACT001 and its major metabolites after single and multiple administration in NMOSD-ON subjects. Secondary objectives: 1) To preliminarily evaluate the anti-inflammatory and relapse-reducing effects of ACT001 in the central nervous system. 2) To explore the recommended dose for Phase II trials. Exploratory objectives: To evaluate the changes in visual function, titer (or concentration) of aquaporin 4 antibody (AQP4 IgG) and other biomarkers before and after administration.